Having trouble viewing this email? View in your browser.
Weekly News
14 December 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

Launch of the new ESCMID eLibrary

We are pleased to launch the new and improved ESCMID eLibrary! Browse webcasts, presentations and abstracts from previous ECCMIDs and other ESCMID events. ESCMID members can access the most recent material, so ensure your membership is valid and up-to-date!

32nd ECCMID Keynote Lecture highlight

We are excited to highlight the fantastic ECCMID 2022 Keynote Lecture ‘Pathogens and the microbiome: antibiotics at the crossroads’ with Martin Blaser (Rutgers University, Piscataway, US). See this and other highlights in the online programme, and be sure to register at the earlybird rate!

ECCMID 2022 Art Gallery – Submit your creative work!

The ECCMID art gallery is still accepting submissions for 2022! Visit the website and submit your work, the best pieces will be awarded with free registration to ECCMID 2022, as well as being featured in an onsite exhibition. Submissions close on December 31, 2021.

Public Consultation Phase open for ESCMID Guidelines

“ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the healthcare setting” is undergoing public consultation. Check here to participate. The deadline to provide feedback and comments is 31 December 2021.

Free ecraid webinar - 19 January 2022, 13:00 (CET)

Be sure to register for the webinar ‘How clinical trials inform antimicrobial stewardship’, which will provide an overview of data from clinical trials in the management of cUTIs and pneumonia, and how this information may be incorporated into AMS activities.

ESCMID is a proud member of ecraid.

TAE SC Election results – 3 New members

In the recent elections, three new TAE SC members were selected, and  will join the committee in April 2022 for three years: Yousra Kherabi (France), Suzanne Aura Victoria van Asten (Netherlands) and Giorgia Caruana (Switzerland). Welcome on board!

Immunogenicity trends after second vaccination among HCWs in Israel

This study evaluated antibody response to the BNT162B2 vaccine among healthcare workers (HCWs). The authors found that most HCWs had measurable antibodies at 3 months with risk factors for lower antibody levels including older age, male sex, underlying condition, and immunosuppressive treatment.